Optimal vancomycin serum level in Staphylococcus aureus infections;Comment optimiser le taux sérique de vancomycine dans le traitement des infections à Staphylococcus aureus ?

Medecine et Maladies Infectieuses

Volumn 36, Issue 9, 2006, Pages 439-442

  Bingen, E ^a   Mariani Kurkdjian, P ^a   Nebbad, B ^b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

MIC; Staphylococcus; Through serum level; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CHRONOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; OTOTOXICITY; PRACTICE GUIDELINE; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; BLOOD; REVIEW;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 33750033588     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.07.016     Document Type: Short Survey

References (36)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998) 29-35
2. Leclerc R. Glycopeptides et Staphylocoques. In: Courvalin P., Leclercq R., and Bingen E. (Eds). Antibiogramme (2006), ESKA, Paris 245-256
3. Saunders N.J. Why measure peak vancomycin levels?. Lancet 344 (1994) 1748-1750
4. Saunders N.J. Vancomycin administration and monitoring reappraisal. J. Antimicrob. Chemother. 36 (1995) 279-282
5. Mellor J.A., Kingdom J., Cafferkey M.T., et al. Vancomycin toxicity: a prospective study. J. Antimicrob. Chemother. 15 (1985) 773-780
6. Rybak M.J., Cappellety D.M., Ruffing M.J., et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for Gram-positive infections. Program and Abstracts of the 37 th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto (1997), American Society for Microbiology, Washington, DC, USA (Abstract A46)
7. Zimmermann A.E., Katona B.G., and Plaisance K.I. Association of vancomycin concentrations with outcome in patients with Gram-positive bacteraemia. Pharmacothérapie 15 (1995) 85-91
8. Miles M.V., Li L., Lakkis H., Youngblood J., and McGinnis P. Special considerations for monitoring vancomycin concentrations in pediatric patients. Ther. Drug Monit. 19 (1997) 265-270
9. Faber B.F., and Moellering Jr. R.C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob. Agents Chemother. 23 (1983) 138-141
10. Reeves D.S., Mac Gowan A.P., Holt H.A., Lovering A.M., Warnock D.W., and White L.O. Therapeutic monitoring of antimicrobials: a summary of the information presented at the UF NEQAS for antibiotic assays meeting for participants, October 1993. J. Antimicrob. Chemother. 35 (1995) 213-226
11. Elting L.S., Rubenstein E.B., Kurtin D., Rolston K.V., Fangtang J., Martin C.G., et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83 (1998) 2597-2607
12. Carbon C. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scand. J. Infect. Dis. 74 (1990) 163-172
13. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42 (2006) S35-S39
14. S are similar. Antimicrob. Agents Chemother. 38 (1994) 2730-2737
15. Mulhern J.G., Braden G.L., O'Shea M.H., Madden R.L., Lipkowitz G.S., and Germain M.J. Through serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am. J. Kidney Dis. 25 (1995) 611-615
16. Drew R.H., Perfect J.R., Srinath L., Kurkimilis E., Dowzicky M., and Talbot G.H. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J. Antimicrob. Chemother. 46 (2000) 775-784
17. Fridkin S.K., Hageman J., McDougal L.K., Mohammed J., Jarvis W.R., Perl T.M., et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vacomycin, 1997-2001. Clin. Infect. Dis. 36 (2003) 429-439
18. Gopal V., Bisno A.L., and Sierblatt F.J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA 236 (1976) 1604-1606
19. Moise P.A., and Schentag J.J. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16 (2000) S31-S34
20. Moise P.A., Forrest A., Birmingham M.C., and Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J. Antimicrob. Chemother. 50 (2002) 1017-1026
21. Sakoulas G., Moise-Broder P.A., Schentag J.J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42 (2004) 2398-2402
22. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38 (2004) 1700-1705
23. Charles P., Ward P., Johnson P., Howden B., and Grayson M. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38 (2004) 448-451
24. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350 (1997) 1670-1673
25. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., and Falagas M.E. Continuous vs intermittent intravenous administration of antibiotics : a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5 (2005) 581-589
26. Garaffo R., and Lavrut T. Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation. Réanimation 14 (2005) 264-275
27. Moise P.A., Forrest A., Bhavnani S.M., Birmingham M.C., and Schentag J.J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Health Syst. Pharm. 57 (2000) S4-S9
28. Potel G., Caillon J., Jacqueline C., Navas D., Kergueris M.-F., and Batard E. Dosage des antibiotiques en réanimation : quand et comment demander et interpréter les tests ?. Réanimation 15 (2006) 187-192
29. Carlet J., and Benali A. Existe t'il une alternative aux glycopeptides pour le traitement des infections à Staphylococcus aureus resistant à la méthicilline. Réanimation 15 (2006) 176-179
30. Gemmell Curtis G., Edwards David I., Fraise Adam P., Gould F., Kate, Ridgway Geoff L., Warren Rod E, on behalf of the Joint Working Party of the British Society for Antimicrobial Chemotherapy, and Hospital Infection Society and Infection Control Nurses Association. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. 57 (2006) 589-608
31. Kitzis M.D., and Goldstein F.W. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin. Microbiol. Infect. Dis. 12 (2006) 81-95
32. Pea F., and Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically III patients. Clin. Infect. Dis. 42 (2006) 1764-1771
33. Harding I., MacGovan A.P., White L.O., Darley E.S., and Reed V. Teicoplanin therapy of Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J. Antimicrob. Chemother. 45 (2000) 835-841
34. Kitzis M.D. Dosage des antibiotiques. In: Courvalin P., Leclercq R., and Bingen E. (Eds). Antibiogramme (2006), ESKA, Paris 653-656
35. Hidayat I. 43e annual IDSA San Francisco (2005)
36. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1 (2001) 147-155